Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brandywine Realty

Boston Properties

City Office REIT

Cousins Properties

Dropbox

General Electric

Kilroy Realty

Microsoft

Phillips 66

Charles Schwab

SL Green Realty

Office REITs are facing challenges as the hybrid work model becomes more popular, leading to downsizing and increased vacancies. Major companies like Charles Schwab, Johnson & Johnson, Dropbox, and Microsoft have already downsized their office spaces. Office REITs like Boston Properties, Kilroy Realty, City Office REIT, and SL Green are experiencing negative cash spreads and declining occupancy rates, indicating more trouble ahead.

Sell Alert: The Slaughter Of Office REITs Is Just Beginning

Coca-Cola

You don't have to make extraordinary moves or time the market to become a successful investor. Instead, following a few simple steps could deliver great gains over time.

Want to Win in the Stock Market? Be Average.

Johnson & Johnson is known for its long track record of dividend growth. The company also has been associated with some of the most well-known consumer health products.

This Dividend Stock Has a $13 Billion Secret Weapon

Archer-Daniels-Midland Company

Aflac

Cummins

Corteva Inc

CVS Health

Dominion Energy

Deere & Company

Discover

Dow Inc

eBay

Con Ed

Elevance Health Inc

Emerson Electric

Eaton

Fortune Brands Innovations Inc

FirstEnergy

W.W. Grainger

Intel

Nordstrom

Jackson Financial

KeyCorp

Kraft Heinz

In December, we (my wife and I) received a dividend income total of $10,193.04. Crossed the $10k threshold, again. Vanguard's High Dividend Yield ETF, which we have been buying for 3.5 years, literally has paid immense dividends.

Dividend Income Summary: Lanny's December 2023 Summary

Johnson & Johnson (JNJ) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would purchase the biotechnology firm to add to its cancer-fighting drug portfolio.

Johnson & Johnson Pays $2 Billion for Ambrx to Boost Its Cancer Drug Pipeline

Large pharma stocks, including Johnson & Johnson, may be experiencing a shift in favor as investors move away from glamour growth stocks as 2024 gets underway. Johnson & Johnson is a leading global healthcare company with a below-market valuation and an attractive dividend yield, though its chart has its issues. Analysts have mixed opinions on Johnson & Johnson, with some citing concerns about its pipeline and slower growth in MedTech.

Johnson & Johnson: EPS Growth Returns In 2024, JPM Healthcare Conference On Tap

Johnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm's marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.

Johnson & Johnson Will Pay $700 Million To Resolve Baby Powder Marketing Probe, Report Says

Merck

Merck and Johnson & Johnson are paying big premiums to acquire companies with promising biotech targets.

Merck and J&J's Biotech Deals Are More Good News for a Troubled Sector

Johnson & Johnson has tentatively agreed to pay about $700 million to resolve an investigation by over 40 U.S. states into claims it wrongfully marketed its talc-based baby powder, Bloomberg News reported on Monday citing people familiar with the deal.

J&J to pay $700 million to settle states' talc-marketing probe - Bloomberg News

Boston Scientific

J&J, Merck and Boston Scientific kicked off the year's biggest medical conference with a trio of takeovers. AMAM stock and HARP stock soared.

J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value

Johnson & Johnson (NYSE:JNJ) has announced its definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company, in an all-cash merger transaction for a total equity value of approximately $2 billion. Ambrx is known for its proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs) for cancer treatment.

Johnson & Johnson to acquire Ambrx for $2B

Ambrx Biopharma Inc

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs.

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

Shares of Ambrx Biopharma Inc (NASDAQ: AMAM) roughly doubled this morning after Johnson & Johnson (NYSE: JNJ) revealed plans of acquiring the clinical-stage biopharmaceutical company. Details of the JNJ-Ambrx deal Johnson & Johnson is willing to pay about $2.0 billion to buy the Nasdaq-listed firm.

Ambrx Biopharma stock doubles on JNJ deal

Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.

Johnson & Johnson to Acquire Amrbx for $2B

Johnson & Johnson JNJ, +0.31% said Monday it has entered into a definitive agreement to acquire Ambrx Biopharma Inc. AMAM, +2.02%. The all-cash merger transaction has a total equity value of approximately $2 billion, or $1.9 billion net of estimated cash acquired, Johnson & Johnson said.

Johnson & Johnson to acquire Ambrx in $2 billion deal

Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma for $2 billion to gain access to its portfolio of targeted cancer therapies.

J&J to buy cancer therapy developer Ambrx for $2 bln

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.

Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Johnson & Johnson's leading product, Stelara, is nearing the end of its exclusivity, which will likely slow down the growth of earnings per share. JNJ prioritizes growth in investments, with a focus on pharmaceuticals, medtech, and potential inorganic growth. JNJ anticipates launching new therapies and targeting key areas in the pharmaceutical and medtech sectors to drive growth.

Johnson & Johnson: Overblown Stelara Concerns Distract From Value

Amgen

Cisco Systems

Chevron

Verizon

The 2024 Dogs of the Dow are particularly homely hounds—which means we're talking big dividends.

News for Johnson & Johnson Stock (JNJ)